Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.5
(-6.44%)
USD 4.5
(-6.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 33.48 Million USD | -13.2% |
| 2022 | 32.89 Million USD | 21.04% |
| 2021 | 27.17 Million USD | -5.61% |
| 2020 | 28.78 Million USD | 6.75% |
| 2019 | 26.96 Million USD | -19.17% |
| 2018 | 33.36 Million USD | -1.23% |
| 2017 | 33.77 Million USD | 24.8% |
| 2016 | 27.06 Million USD | -5.2% |
| 2015 | 28.55 Million USD | -10.35% |
| 2014 | 31.84 Million USD | 19.79% |
| 2013 | 26.58 Million USD | -39.3% |
| 2012 | 43.8 Million USD | -4.31% |
| 2011 | 45.78 Million USD | 8.25% |
| 2010 | 42.28 Million USD | 7.33% |
| 2009 | 39.4 Million USD | 23.01% |
| 2008 | 32.02 Million USD | 26.13% |
| 2007 | 25.39 Million USD | 64.72% |
| 2006 | 15.41 Million USD | 51.79% |
| 2005 | 10.15 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 5.77 Million USD | -12.92% |
| 2024 Q2 | 6.99 Million USD | 21.26% |
| 2023 Q2 | 9.36 Million USD | 17.48% |
| 2023 Q4 | 6.62 Million USD | -20.34% |
| 2023 FY | 28.54 Million USD | -13.2% |
| 2023 Q3 | 8.32 Million USD | -11.18% |
| 2023 Q1 | 7.97 Million USD | 23.19% |
| 2022 Q2 | 8.26 Million USD | -7.76% |
| 2022 Q3 | 9.18 Million USD | 11.14% |
| 2022 FY | 32.89 Million USD | 21.04% |
| 2022 Q4 | 6.47 Million USD | -29.55% |
| 2022 Q1 | 8.96 Million USD | 79.46% |
| 2021 Q4 | 4.99 Million USD | -25.95% |
| 2021 Q3 | 6.74 Million USD | -7.8% |
| 2021 Q2 | 7.31 Million USD | -9.91% |
| 2021 Q1 | 8.11 Million USD | 1.55% |
| 2021 FY | 27.17 Million USD | -5.61% |
| 2020 Q3 | 7.1 Million USD | 1.71% |
| 2020 FY | 28.78 Million USD | 6.75% |
| 2020 Q1 | 6.69 Million USD | -38.34% |
| 2020 Q2 | 6.98 Million USD | 4.36% |
| 2020 Q4 | 7.99 Million USD | 12.49% |
| 2019 FY | 26.96 Million USD | -19.17% |
| 2019 Q1 | 9.9 Million USD | -6.85% |
| 2019 Q4 | 10.86 Million USD | 28.52% |
| 2019 Q3 | 8.45 Million USD | -11.69% |
| 2019 Q2 | 9.56 Million USD | -3.38% |
| 2018 Q1 | 7.05 Million USD | -25.65% |
| 2018 FY | 33.36 Million USD | -1.23% |
| 2018 Q4 | 10.63 Million USD | 51.19% |
| 2018 Q3 | 7.03 Million USD | -18.61% |
| 2018 Q2 | 8.64 Million USD | 22.39% |
| 2017 Q1 | 8.25 Million USD | 10.42% |
| 2017 FY | 33.77 Million USD | 24.8% |
| 2017 Q4 | 9.49 Million USD | 5.15% |
| 2017 Q3 | 9.03 Million USD | 29.04% |
| 2017 Q2 | 6.99 Million USD | -15.23% |
| 2016 Q2 | 6.25 Million USD | -3.9% |
| 2016 Q3 | 6.81 Million USD | 8.92% |
| 2016 Q4 | 7.47 Million USD | 9.65% |
| 2016 FY | 27.06 Million USD | -5.2% |
| 2016 Q1 | 6.51 Million USD | 1.01% |
| 2015 Q2 | 7.67 Million USD | 1.96% |
| 2015 FY | 28.55 Million USD | -10.35% |
| 2015 Q1 | 7.52 Million USD | -5.57% |
| 2015 Q4 | 6.44 Million USD | -6.61% |
| 2015 Q3 | 6.9 Million USD | -10.01% |
| 2014 Q4 | 7.96 Million USD | -5.02% |
| 2014 FY | 31.84 Million USD | 19.79% |
| 2014 Q2 | 8.45 Million USD | 20.06% |
| 2014 Q1 | 7.03 Million USD | 17.04% |
| 2014 Q3 | 8.38 Million USD | -0.73% |
| 2013 FY | 26.58 Million USD | -39.3% |
| 2013 Q4 | 6.01 Million USD | 9.4% |
| 2013 Q1 | 9.14 Million USD | -20.6% |
| 2013 Q2 | 5.92 Million USD | -35.23% |
| 2013 Q3 | 5.49 Million USD | -7.23% |
| 2012 Q1 | 9.4 Million USD | -15.1% |
| 2012 FY | 43.8 Million USD | -4.31% |
| 2012 Q2 | 11.26 Million USD | 19.73% |
| 2012 Q3 | 11.6 Million USD | 3.07% |
| 2012 Q4 | 11.52 Million USD | -0.74% |
| 2011 Q2 | 13.1 Million USD | 32.66% |
| 2011 Q4 | 11.08 Million USD | -5.4% |
| 2011 FY | 45.78 Million USD | 8.25% |
| 2011 Q3 | 11.71 Million USD | -10.63% |
| 2011 Q1 | 9.87 Million USD | -16.7% |
| 2010 Q3 | 11.28 Million USD | 14.23% |
| 2010 FY | 42.28 Million USD | 7.33% |
| 2010 Q4 | 11.86 Million USD | 5.13% |
| 2010 Q1 | 9.27 Million USD | -5.87% |
| 2010 Q2 | 9.87 Million USD | 6.52% |
| 2009 Q2 | 9.04 Million USD | 4.29% |
| 2009 Q1 | 8.67 Million USD | -3.58% |
| 2009 Q3 | 11.83 Million USD | 30.89% |
| 2009 FY | 39.4 Million USD | 23.01% |
| 2009 Q4 | 9.84 Million USD | -16.79% |
| 2008 Q2 | 7.62 Million USD | 0.95% |
| 2008 Q1 | 7.54 Million USD | 13.1% |
| 2008 Q4 | 8.99 Million USD | 14.32% |
| 2008 Q3 | 7.86 Million USD | 3.24% |
| 2008 FY | 32.02 Million USD | 26.13% |
| 2007 Q2 | 6.73 Million USD | 26.21% |
| 2007 Q1 | 5.33 Million USD | 4.53% |
| 2007 Q4 | 6.67 Million USD | 0.37% |
| 2007 Q3 | 6.64 Million USD | -1.26% |
| 2007 FY | 25.39 Million USD | 64.72% |
| 2006 FY | 15.41 Million USD | 51.79% |
| 2006 Q1 | 1.36 Million USD | 0.0% |
| 2006 Q4 | 5.1 Million USD | 2.21% |
| 2006 Q2 | 3.95 Million USD | 190.87% |
| 2006 Q3 | 4.99 Million USD | 26.19% |
| 2005 FY | 10.15 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 89.032% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -12.55% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 89.734% |
| Cosmos Health Inc. | 4.34 Million USD | -669.867% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1489.355% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 54.171% |
| Cronos Group Inc. | 6.99 Million USD | -378.993% |
| Incannex Healthcare Limited | 12 Thousand USD | -278949.133% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 11151.451% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 19.986% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 4591.206% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -301.549% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -301.549% |
| SCYNEXIS, Inc. | 124.51 Million USD | 73.107% |
| Safety Shot Inc | -74.45 Thousand USD | 45073.469% |
| Theratechnologies Inc. | 62.12 Million USD | 46.103% |
| Alpha Teknova, Inc. | 10.29 Million USD | -225.232% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -232.271% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 93.17% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -605.709% |
| Dynavax Technologies Corporation | 182.11 Million USD | 81.613% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 92.41% |
| Radius Health, Inc. | 307.71 Million USD | 89.118% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -5944.702% |
| Alvotech | -69.42 Million USD | 148.235% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 92.224% |
| SIGA Technologies, Inc. | 122.09 Million USD | 72.573% |
| Shineco, Inc. | 882.16 Thousand USD | -3695.864% |
| Silver Spike Investment Corp. | 8.1 Million USD | -313.274% |
| Journey Medical Corporation | 52.52 Million USD | 36.243% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -698.963% |
| Embecta Corp. | 749.9 Million USD | 95.535% |
| Harrow Health, Inc. | 90.55 Million USD | 63.021% |
| Procaps Group, S.A. | 239.56 Million USD | 86.022% |
| Biofrontera Inc. | 16.62 Million USD | -101.395% |
| DURECT Corporation | 6.83 Million USD | -390.205% |
| PainReform Ltd. | -15 Thousand USD | 223339.307% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 93.606% |
| OptiNose, Inc. | 62.35 Million USD | 46.297% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -996.398% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 89.191% |
| ProPhase Labs, Inc. | 16.23 Million USD | -106.207% |
| Phibro Animal Health Corporation | 312.48 Million USD | 89.284% |
| Procaps Group S.A. | 239.56 Million USD | 86.022% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -2471.881% |
| Viatris Inc. | 6.43 Billion USD | 99.48% |
| Rockwell Medical, Inc. | 8.7 Million USD | -284.718% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 38.655% |
| Tilray Brands, Inc. | 223.35 Million USD | 85.008% |
| PetIQ, Inc. | 252.74 Million USD | 86.751% |
| Talphera, Inc. | -4.89 Million USD | 784.084% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 98.187% |
| Alimera Sciences, Inc. | 61.17 Million USD | 45.258% |
| Assertio Holdings, Inc. | 125.04 Million USD | 73.222% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 491744.34% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -23.487% |
| Hempacco Co., Inc. | -1.21 Million USD | 2854.153% |
| Alvotech | -69.42 Million USD | 148.235% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 95.281% |
| Kamada Ltd. | 52.59 Million USD | 36.33% |
| Currenc Group, Inc. | 17.35 Million USD | -92.932% |
| Indivior PLC | 907 Million USD | 96.308% |
| Evoke Pharma, Inc. | 4.97 Million USD | -572.576% |
| Flora Growth Corp. | 17.73 Million USD | -88.781% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1489.355% |
| Evolus, Inc. | 140.52 Million USD | 76.171% |
| HUTCHMED (China) Limited | 453.55 Million USD | 92.617% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 90.265% |
| Akanda Corp. | 111.44 Thousand USD | -29945.937% |